Megan Leila Baker, MD
she/her/hers
About
Titles
Clinical Associate
Education & Training
- PhD
- Yale University Graduate School of Arts and Sciences, Investigative Medicine (2026)
- Research Fellow
- Yale School of Medicine (2024)
- Clinical Fellow
- Yale School of Medicine (2023)
- Resident
- Yale School of Medicine (2021)
- MD
- Wayne State University School of Medicine (2018)
- BS
- University of Michigan, Biomolecular Science, Neuroscience (2014)
Board Certifications
Nephrology
- Certification Organization
- ABIM
- Original Certification Date
- 2023
Internal Medicine
- Certification Organization
- ABIM
- Original Certification Date
- 2021
Research
Publications
Featured Publications
The Lymphatic System in Kidney Disease
Baker M, Cantley L. The Lymphatic System in Kidney Disease. Kidney360 2023, 4: e841-e850. PMID: 37019177, PMCID: PMC10371377, DOI: 10.34067/kid.0000000000000120.Peer-Reviewed Original ResearchConceptsKidney diseaseLymphatic systemSetting of AKIKidney allograft rejectionNormal kidney functionImmune response modulationAllograft rejectionLymph nodesInflammatory infiltrateKidney functionImmune cellsTissue edemaNovel therapiesImmune surveillanceNumerous disease statesSystemic circulationFluid removalKidney tissueResident cellsTherapeutic potentialSurveillance cellsAKIDisease statesKidneyResponse modulationNSAIDs in CKD: Are They Safe?
Baker M, Perazella MA. NSAIDs in CKD: Are They Safe? American Journal Of Kidney Diseases 2020, 76: 546-557. PMID: 32479922, DOI: 10.1053/j.ajkd.2020.03.023.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonsteroidal anti-inflammatory drugsChronic kidney diseaseGlomerular filtration rateFiltration rateRisk factorsHigh pain burdenAcute kidney injuryManagement of painAnti-inflammatory drugsCKD populationNSAID useKidney injuryPain burdenPain controlHeart failureComorbid conditionsElectrolyte derangementsKidney diseaseSafety dataDrug effectsPatientsIndividualized basisDrug metabolismProgressive lossCautious use
2023
Incidence and outcomes of acute kidney injury including hepatorenal syndrome in hospitalized patients with cirrhosis in the US
Patidar K, Belcher J, Regner K, St. Hillien S, Simonetto D, Asrani S, Neyra J, Sharma P, Velez J, Wadei H, Nadim M, Chung R, Seethapathy R, Parada X, Ouyang T, Ufere N, Robinson J, Diaz P, Wilechansky R, Przybyszewski E, Smith T, Ali A, Orman E, Schulz P, Siddiqui S, Shabbir R, Liu L, Cama-Olivares A, Flannery A, Baker M, Gunasekaran D, Aswine A, Issa R, Li J, Verma S, Chalmers D, Varghese V, Lam W, Mohamed M, Kovacic R, Gaddy A, Attieh R, Cortes P, Semnani S, Wang L, Khemichian S, Allegretti A, consortium F. Incidence and outcomes of acute kidney injury including hepatorenal syndrome in hospitalized patients with cirrhosis in the US. Journal Of Hepatology 2023, 79: 1408-1417. PMID: 37517455, PMCID: PMC10807505, DOI: 10.1016/j.jhep.2023.07.010.Peer-Reviewed Original ResearchConceptsEtiology of AKIHRS-AKISubdistribution hazard ratiosHepatorenal syndromePrerenal AKIKidney injuryHigh morbidityIncidence ratePractice patternsSimilar outcomesHigher AKI stageAcute kidney injuryRetrospective cohort studyAcute tubular necrosisConsecutive adult patientsEtiology of injuryAKI stageAKI definitionLiver transplantAdult patientsCohort studyHazard ratioSevere complicationsTubular necrosisComplete responsePersonalised recommendations for hospitalised patients with Acute Kidney Injury using a Kidney Action Team (KAT-AKI): protocol and early data of a randomised controlled trial
Aklilu A, O’Connor K, Martin M, Yamamoto Y, Coronel-Moreno C, Shvets K, Jones C, Kadhim B, Corona-Villalobos C, Baker M, Tan J, Freeman N, Groener M, Menez S, Brown D, Culli S, Lindsley J, Orias M, Parikh C, Smith A, Sundararajan A, Wilson F. Personalised recommendations for hospitalised patients with Acute Kidney Injury using a Kidney Action Team (KAT-AKI): protocol and early data of a randomised controlled trial. BMJ Open 2023, 13: e071968. PMID: 37068906, PMCID: PMC10111926, DOI: 10.1136/bmjopen-2023-071968.Peer-Reviewed Original ResearchConceptsPrimary teamAcute Kidney Injury OutcomesAKI alert systemInvestigator-blinded trialUsual care armKey secondary outcomesClinical decision support toolIntensive care unitUS hospital systemAKI alertsAKI detectionAKI progressionCare armSecondary outcomesPrimary outcomeCare unitMedian timeMedical floorPercentage of recommendationsDiagnostic interventionsInjury outcomesRandomisationHospital systemEthics CommitteeDedicated team
2022
Strongyloides stercoralis infection identified on urine microscopy
Baker ML, Brewster UC. Strongyloides stercoralis infection identified on urine microscopy. BMJ Case Reports 2022, 15: e250078. PMID: 35379686, PMCID: PMC8981339, DOI: 10.1136/bcr-2022-250078.Peer-Reviewed Case Reports and Technical NotesMortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy
Baker ML, Yamamoto Y, Perazella MA, Dizman N, Shirali AC, Hafez N, Weinstein J, Simonov M, Testani JM, Kluger HM, Cantley LG, Parikh CR, Wilson FP, Moledina DG. Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy. Journal For ImmunoTherapy Of Cancer 2022, 10: e004421. PMID: 35354588, PMCID: PMC8968986, DOI: 10.1136/jitc-2021-004421.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisAcute kidney injuryImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyICI therapyKidney injuryInhibitor therapyInterstitial nephritisTime-varying Cox proportional hazards modelsHigher peak serum creatinineSevere acute kidney injuryCancer typesCox proportional hazards modelAssociations of biopsyBaseline laboratory valuesObservational cohort studyPeak serum creatinineFavorable treatment responseProportional hazards modelAKI patientsTherapy initiationCohort studySerum creatinineUnivariable analysisImmune activationImaging Modalities for Acute Tubulointerstitial Nephritis
Baker M, Perazella M. Imaging Modalities for Acute Tubulointerstitial Nephritis. 2022, 257-266. DOI: 10.1007/978-3-030-93438-5_20.ChaptersAcute tubulointerstitial nephritisTubulointerstitial nephritisAcute kidney injury diagnosisNonspecific constitutional symptomsChronic kidney diseaseImaging modalitiesCurrent imaging modalitiesEmission Tomography ImagingPositron emission tomography (PET) imagingNon-invasive diagnosisConstitutional symptomsFlank painMost patientsKidney diseaseKidney failureCase reportInjury diagnosisRadiographic cluesClinical dataCommon causeGallium uptakeCharacteristic signsSymptomsDiagnosisTomography imaging
2021
AKI and Mortality in Patients Prescribed Immune Checkpoint Inhibitor Therapy
Baker M, Yamamoto Y, Perazella M, Parikh C, Wilson F, Moledina D. AKI and Mortality in Patients Prescribed Immune Checkpoint Inhibitor Therapy. Journal Of The American Society Of Nephrology 2021, 32: 132-132. DOI: 10.1681/asn.20213210s1132c.Peer-Reviewed Original Research
2020
Can NSAIDs Be Used Safely for Analgesia in Patients with CKD?: COMMENTARY.
Baker ML, Perazella MA. Can NSAIDs Be Used Safely for Analgesia in Patients with CKD?: COMMENTARY. Kidney360 2020, 1: 1192-1194. PMID: 35372870, PMCID: PMC8815502, DOI: 10.34067/kid.0004652020.Commentaries, Editorials and LettersSGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern?
Baker ML, Perazella MA. SGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern? Journal Of Nephrology 2020, 33: 985-994. PMID: 32067179, DOI: 10.1007/s40620-020-00712-5.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType 2 diabetes mellitusAcute kidney injuryChronic kidney diseaseDiabetes mellitusKidney diseaseKidney injuryAlbuminuric chronic kidney diseaseEnd-stage kidney diseaseInhibitor drugsSGLT2 inhibitor therapySignificant cardiovascular benefitsHeart failure hospitalizationGlomerular filtration rateAtherosclerotic cardiovascular diseaseLarge clinical trialsFDA adverse eventsBeneficial cardiovascularKidney benefitsSGLT2 transporterCardiovascular deathFailure hospitalizationAdverse eventsCardiovascular benefitsKidney protectionBlood pressure